Navigation path

Themes
Agriculture & food
Energy
Environment
ERA-NET
Health & life sciences
Human resources & mobility
Industrial research
Information society
Innovation
International cooperation
Nanotechnology
Pure sciences
Research infrastructures
Research policy
Science & business
Science in society
Security
SMEs
Social sciences and humanities
Space
Special Collections
Transport

Countries
Countries
  Argentina
  Australia
  Austria
  Belarus
  Belgium
  Benin
  Botswana
  Brazil
  Bulgaria
  Burkina Faso
  Cameroon
  Canada
  Chile
  China
  Colombia
  Croatia
  Cyprus
  Czech Republic
  Denmark
  Egypt
  Estonia
  Ethiopia
  Finland
  France
  Gambia
  Georgia
  Germany
  Ghana
  Greece
  Hungary
  Iceland
  India
  Indonesia
  Ireland
  Israel
  Italy
  Japan
  Kazakhstan
  Kenya
  Korea
  Latvia
  Lichtenstein
  Lithuania
  Luxembourg
  Madagascar
  Malaysia
  Malta
  Mexico
  Montenegro
  Morocco
  Mozambique
  Namibia
  Netherlands
  New Zealand
  Nigeria
  Norway
  Panama
  Peru
  Poland
  Portugal
  Romania
  Russia
  Senegal
  Serbia
  Slovakia
  Slovenia
  South Africa
  Spain
  Sri Lanka
  Swaziland
  Sweden
  Switzerland
  Taiwan
  Tanzania
  Thailand
  Tunisia
  Turkey
  Uganda
  Ukraine
  United Kingdom
  United States
  Vietnam


   Infocentre

Last Update: 12-08-2014  
Related category(ies):
Health & life sciences  |  Industrial research  |  International cooperation  |  Nanotechnology  |  SMEs

 

Countries involved in the project described in the article:
Belgium  |  Denmark  |  France  |  Germany  |  Israel  |  Italy  |  Netherlands  |  Norway  |  Poland  |  Spain  |  Switzerland  |  United Kingdom
Add to PDF "basket"

Finding a better way to help treat disease

Many potential drugs that have the desired effect in the laboratory never make it onto clinical trials because they may cause serious side-effects or simply cannot be absorbed by the human body.

Illustration of nanorobots

© I.M.Redesiuk - Fotolia

To bypass these negative reactions, the European Union (EU)-funded research project Meditrans has developed smart drug delivery systems to help treat diseases such as cancer and rheumatoid arthritis more accurately.

The project team relied on nanomedicine – a process that uses carrier materials like tiny tubes and nanoparticles – to deliver exact quantities of drug to specific body organs and cells. “This means that the amount of required drug and side-effects could be significantly reduced by depositing the medication in the affected area only and in no higher dose than necessary,” says Meditrans coordinator, Dr. Gert Storm at Utrecht University in the Netherlands.

A key result of the Meditrans project was the imaging method developed by the team to monitor the various steps in the targeted drug delivery process. These so-called 'MRI imaging probes' reported on the location of nanomedicines in the body, the drug release process and the end result for the patient. Furthermore, the project team assessed the toxicity of selected nanomedicines – a crucial step for their further development.

“Overall, our approach is more effective and less toxic. It could also significantly reduce drug consumption and treatment expenses, easing the burden on healthcare systems across Europe and beyond,” explains Storm.

The Meditrans project has already shown its potential in tests and the team has identified four nanomedicines that will be further explored. If all goes well, each of the four nanomedicines will be commercialised by an industrial partner and eventually be available on the market.

The research team also held training courses at regular intervals during the project. The courses were targeted at scientists, SMEs and key stakeholders across the globe. Moreover, all project partners had access to the Galenos Network in Pharmaceutical Sciences. Founded in 1995, this network was set up to promote and foster the training of young researchers in the scientific area of Advanced Drug Delivery.

Meditrans project has created a strong link between the community of pharmaceutical scientists and imaging probe developers. It is expected that this link will boost the emerging field of imaging-guided drug delivery in Europe. To ensure that its legacy lives on, the project's results have been disseminated across Europe in the media, scientific articles and through events.

 

Project details

  • Project acronym: MEDITRANS
  • Participants: Netherlands (Coordinator), France, Germany, Norway, Poland, Belgium, UK, Italy, Israel, Spain, Switzerland, Denmark
  • Project FP7 26668
  • Total costs: € 14 839 172
  • EU contribution: € 10 728 701
  • Duration: January 2007 - March 2011

Convert article(s) to PDF

No article selected


loading


Search articles

Notes:
To restrict search results to articles in the Information Centre, i.e. this site, use this search box rather than the one at the top of the page.

After searching, you can expand the results to include the whole Research and Innovation web site, or another section of it, or all Europa, afterwards without searching again.

Please note that new content may take a few days to be indexed by the search engine and therefore to appear in the results.

Print Version
Share this article
See also
Project web site
Project information on CORDIS






  Top   Research Information Center